Search

Displaying results 4661 - 4670 of 7283 in total
  1. Drug

    Dapansutrile

    go.drugbank.com/drugs/DB16130
    Investigational

    Dapansutrile is under investigation in clinical trial NCT01768975 (Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee).

  2. Drug

    Tisotumab vedotin

    go.drugbank.com/drugs/DB16732
    ApprovedInvestigational

    agent, via a protease-cleavable valine-citrulline linker. … On April 29, 2024, tisotumab vedotin was granted full FDA approval.

  3. Drug

    Psilocybin

    go.drugbank.com/drugs/DB11664
    Investigational

    In November, 2019, it was granted Breakthrough Therapy status by the FDA.

  4. Drug

    INVAC-1

    go.drugbank.com/drugs/DB16196
    Investigational

    INVAC-1 is under investigation in clinical trial NCT03265717 (DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (Htert), Invac-1 in Chronic Lymphocytic Leukemia).

    Synonyms: Human telomerase reverse transcriptase (htert) dna vaccine invac-1, Invac-1, a double stranded dna plasmid vaccine construct encoding ubiquitin-human telomerase reverse transcriptase (htert) fusion protein
  5. Drug

    Prademagene zamikeracel

    go.drugbank.com/drugs/DB17895
    ApprovedInvestigational

    [L53008] Prademagene zamikeracel was first approved by the FDA on April 29, 2025, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a skin disorder associated with excessive blistering … [L53008] COL7A1 encodes type VII collagen (C7), which is a major component of anchoring fibrils (AF) that are critical for dermal-epidermal cohesion.

    Categories: Complex Mixtures
  6. Drug

    αAβ–Gas6

    go.drugbank.com/drugs/DB17069
    Experimental

    of AD. … It is made of a single chain variable fragment (scFv) of an Amyloid β (Aβ)-targeting monoclonal antibody fused with a truncated receptor binding domain of growth arrest-specific 6 (Gas6), which is a ligand

  7. Drug

    ZYCOV-D

    go.drugbank.com/drugs/DB15892
    Experimental

    The vaccine was developed using a DNA vaccine platform with a non-replicating and non-integrating plasmid carrying the gene of interest[L16503]. … The ZYCOV-D vaccine candidate was developed by Cadila Healthcare Ltd. based in India[A219758].

  8. Drug

    Lisavanbulin

    go.drugbank.com/drugs/DB15224
    Investigational

    Lisavanbulin is under investigation in clinical trial NCT02895360 (Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma).

  9. Drug

    Dendritic cells vaccine

    go.drugbank.com/drugs/DB15803
    Investigational

    The recombinant chimeric DC vaccine is a subunit-based vaccine candidate investigated for safety and effectiveness against SARS-CoV-2-induced pneumonia. … With a better safety profile than inactivated and live-attenuated virus and virus-vector vaccines, the recombinant chimeric DC vaccine reduces the risk of virulence recovery, pre-existing anti-vector immunity

    Synonyms: Recombinant chimeric COVID-19 DC vaccine, Recombinant chimeric COVID-19 epitope DC vaccine;
  10. Drug

    Licofelone

    go.drugbank.com/drugs/DB04725
    Experimental

    It is currently under evaluation as a treatment for osteoarthritis (OA), the most common form of arthritis. … Although phase III trials have been successfully completed in OA patients no dates for regulatory submission have yet been given.